Thursday, December 02, 2021 7:45:42 AM
OR, it seems to me that they have gotten more warrant money in the past 6-12 months than was needed to cover the day-to-day operations by the pace that was established for a couple years now. There are people closer to these numbers than me. Where has that money been put to use? It looks to me like some of it went to Swaston build-out and staffing, but I think perhaps there should still be a little left over for perhaps a new Cognate contract as well.
Now they have $20M banked. If you believe like me that approval is coming before mid-February, and TLD publication and Swaston approval will preceed that which will lead to more warrants being exercised and they have no intention of initially hiring a sales force but will rely on CRL or one of the contract staffers to run a customer service line only. Then that may be just enough money to do the bare bones necessary to be ready to manufacture and distribute drug. I have no idea how they intend to get insurance coverage or support physicians and patients with that process and/or subsidize those needing help without commercial operations but maybe they plan to start slow and grow or sell themselves first.
OR maybe they already have the outline of a partnership/BO deal in place and all they need to do now is get the essentials in place before Merck, BMS, Amgen, Roche, Gilead, etc, etc take over. The thing I don’t like about this is just that, the list that can be made. Why would you lock someone in rather than create a bidding war?
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
FEATURED Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) • Mar 16, 2026 8:37 AM
Record Gold Prices Reshape Economics of New Mine Development • KGC • Mar 16, 2026 9:00 AM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
C2 Blockchain Reports 803 Million DOG (Bitcoin) Holdings Following Strategic Accumulation of Bitcoin-Native Digital Assets • CBLO • Mar 10, 2026 8:00 AM
